ライフサイエンスコーパス: pulmonary complication

1 cell transplantation rapidly corrected this pulmonary complication.

2 icians must remain vigilant to its potential pulmonary complication.

3 associated with fewer severe infections and pulmonary complications.

4 ical outcomes, and management of cardiac and pulmonary complications.

5 ay lead to reduction of severe postoperative pulmonary complications.

6 ood of OSA, postoperative desaturations, and pulmonary complications.

7 per year, P < 0.001) independently predicted pulmonary complications.

8 ary to reduce the incidence of postoperative pulmonary complications.

9 who are at increased risk for postoperative pulmonary complications.

10 offer the potential of decreasing associated pulmonary complications.

11 xperience an increased risk of perioperative pulmonary complications.

12 predisposed to infectious and noninfectious pulmonary complications.

13 idural analgesia in preventing postoperative pulmonary complications.

14 ith underlying conditions, for postoperative pulmonary complications.

15 fear for increasing anastomotic leakage and pulmonary complications.

16 to clearly or possibly reduce postoperative pulmonary complications.

17 ith increased mortality, which may be due to pulmonary complications.

18 of the evidence of interventions to prevent pulmonary complications.

19 patients at risk of developing postoperative pulmonary complications.

20 gic perturbations, and its ability to reduce pulmonary complications.

21 e to factors aimed at reducing postoperative pulmonary complications.

22 n these patients and increasing the risk for pulmonary complications.

23 bclinical population of patients at risk for pulmonary complications.

24 predisposes to development of noninfectious pulmonary complications.

25 ndard low PEEP, did not reduce postoperative pulmonary complications.

26 nical and renal complications, but decreased pulmonary complications.

27 atopoietic cell transplant increases risk of pulmonary complications.

28 king agents is associated with postoperative pulmonary complications.

29 ated with an increased risk of postoperative pulmonary complications.

30 iated with a decreased risk of postoperative pulmonary complications.

31 anaesthesia might be linked to postoperative pulmonary complications.

32 against the increased risk of postoperative pulmonary complications.

33 level of PEEP, did not reduce postoperative pulmonary complications.

34 toperative recovery and a marked decrease in pulmonary complications.

35 e times and the rate of 30-day postoperative pulmonary complications.

36 tive hypoxemia, Sao2 level, or postoperative pulmonary complications.

37 atric surgery at high risk for postoperative pulmonary complications.

38 s not associated with clinically significant pulmonary complications.

39 COVID-19 pneumonia exhibits several extra-pulmonary complications.

40 lation with the development of postoperative pulmonary complications.

41 nal failure, septic shock, and postoperative pulmonary complications.

42 anged from 0.757 for infectious to 0.897 for pulmonary complications.

43 with death in the first decade due to cardio-pulmonary complications.

44 ssure are associated with more postoperative pulmonary complications.

45 The sample allowed a 75% power to detect pulmonary complications (1% vs. 5%) between the two trea

46 iate group had a significantly lower rate of pulmonary complications (11.1% versus 27.8%; P = 0.012).

47 perative bleeding (17%), septic shock (16%), pulmonary complications (15%), and organ-space infection

48 Twenty-six had pulmonary complications (19%).

49 Pulmonary complications (23.9%), renal failure (12.5%),

50 ients with POAF demonstrated higher rates of pulmonary complications (24.0% vs. 11.2%, *p < .01), ana

51 morbidity (>/=grade III), mostly related to pulmonary complications (25.7%), anastomotic leakage (15

52 trial arrhythmia (27% vs 19%; P = 0.013) and pulmonary complications (27% vs 20%; P = 0.016).

53 gastrointestinal complications (11.3%), and pulmonary complications (3.6%).

54 ]), splenic complications (6 of 144 [4.2%]), pulmonary complications (36 of 144 [25.0%]), kidney dise

55 kidney injury (12.7% vs 4.6%, P = .032), and pulmonary complications (38.2% vs 24.1%, P = .017).

56 The leading causes of hospital death were pulmonary complications (45.5%) and progression of malig

57 icantly associated with a lower incidence of pulmonary complications (46.7% vs 31.9%), recurrent lary

58 participants; OR, 0.26; 95% CI, 0.09-0.76), pulmonary complications (9 studies, 1019 participants; O

59 Pulmonary complications account for significant morbidit

60 selectively improved risk stratification for pulmonary complications across at-risk primary cancer di

61 Outcomes examined included bacteremia, pulmonary complications, acute renal failure, shock, int

62 enhance physician awareness of postoperative pulmonary complications, advance postoperative pulmonary

63 Postoperative complications, especially pulmonary complications, affect more than half the patie

64 olitis obliterans (BO) is a detrimental late pulmonary complication after allogeneic hematopoietic st

65 arterial oxygen saturation (Sao2) level, and pulmonary complications after bariatric surgery.

66 lped predict the occurrence of postoperative pulmonary complications after cardiac surgery independen

67 patients at increased risk of postoperative pulmonary complications after cardiac surgery.

68 e ventilation has been recommended to reduce pulmonary complications after cardiac surgery.

69 acute respiratory distress syndrome or cause pulmonary complications after general anesthesia.

70 d 400 adults at intermediate to high risk of pulmonary complications after major abdominal surgery to

71 allow risk stratification for postoperative pulmonary complications after noncardiothoracic surgery.

72 ient- and procedure-related risk factors for pulmonary complications after surgery, the role of preop

73 factors for the development of postoperative pulmonary complications allows targeted interventions ai

74 The influence of this pulmonary complication, along with the omission of bleom

75 associated with adverse outcomes, including pulmonary complications, anastomotic leakage, prolonged

76 cted individuals is associated with multiple pulmonary complications and a poor prognosis.

77 PLDRH reduced the incidence of postoperative pulmonary complications and afforded better short-term p

78 spirometry decreases rates of postoperative pulmonary complications and hospital lengths of stay.

79 Pulmonary complications and hypoxemia are common in sick

80 6.9; P < 0.05) and an increased incidence of pulmonary complications and increased hospital costs.

81 dy presents an estimate for both severity of pulmonary complications and intensity of respiratory the

82 univariate analysis showed that MIE reduced pulmonary complications and length of hospital stay.

83 stomosis, methods to reduce the incidence of pulmonary complications and optimizing fluid management

84 me and the association between occurrence of pulmonary complications and outcome in these patients.

85 was associated with an increase in total and pulmonary complications and reoperation rate.

86 MIE was associated with increased total and pulmonary complications and reoperations; however, benef

87 survival rate of BMT patients who developed pulmonary complications and required mechanical ventilat

88 roach has been shown to reduce postoperative pulmonary complications and shorten hospital length of s

89 ve shown that MIE is associated with reduced pulmonary complications and shorter hospital stay as com

90 w will discuss the etiology of postoperative pulmonary complications and the interventions that reduc

91 e of clinical risk factors for postoperative pulmonary complications and the value of preoperative te

92 a to reduce postoperative cardiovascular and pulmonary complications and there is also consistent evi

93 jury, ileus, stroke, venous thromboembolism, pulmonary complications, and all-cause in-hospital morta

94 sthetic techniques in reducing postoperative pulmonary complications, and also to define the nature o

95 [PEEP] expressed as cm H2O), development of pulmonary complications, and clinical outcomes.

96 l transplantation (HSCT) have a high rate of pulmonary complications, and in this immunosuppressed po

97 recurrent MI, cardiac death, heart failure, pulmonary complications, and major bleeding events.

98 ganisms were less likely to have bacteremia, pulmonary complications, and shock, and were less likely

99 ajor postoperative overall complications and pulmonary complications appeared to be independent risk

100 Postoperative pulmonary complications are a major contributor to the o

101 Therapy-related pulmonary complications are among the leading causes of

102 Postoperative pulmonary complications are as frequent and clinically i

103 Postoperative pulmonary complications are as prevalent as cardiac comp

104 Pulmonary complications are common after coronary artery

105 Pulmonary complications are common and may contribute to

106 Pulmonary complications are common following hematopoiet

107 Postoperative pulmonary complications are common in patients with Amer

108 Postoperative pulmonary complications are common, are associated with

109 Pulmonary complications are common.

110 Transfusion-related pulmonary complications are leading causes of morbidity

111 ith good pulmonary reserve, if postoperative pulmonary complications are reduced, or if complications

112 Pulmonary complications are responsible for high morbidi

113 Rationale: "Noninfectious" pulmonary complications are significant causes of morbid

114 Other than relapse, pulmonary complications are the most common cause of mor

115 lmonary complications, advance postoperative pulmonary complications as a substantive public health c

116 of inflammation, causing unexplained chronic pulmonary complications as seen in some patients during

117 Initial knowledge established pulmonary complications as the chief symptom, however, t

118 supporting strategies to reduce the risk of pulmonary complications as they apply to Mr A.

119 %) in the hybrid-procedure group had a major pulmonary complication, as compared with 31 of 103 (30%)

120 n, etoposide and platinum (BEPx4) to prevent pulmonary complications, as these patients require exten

121 tic Surgery and Its Effects on Postoperative Pulmonary Complications (AVATaR) study.

122 iplinary team developed a strategy to reduce pulmonary complications based on comprehensive patient a

123 There was a dose-dependent increase in pulmonary complications based on pack-year exposure with

124 often face late-onset adverse effects, with pulmonary complications being particularly common.

125 lications with abdominal wound infection and pulmonary complications being the 2 most frequent.

126 Postoperative pulmonary complications can be a devastating consequence

127 the incidence of serious cardiovascular and pulmonary complications can be minimized.

128 comes as VAMIE but was associated with fewer pulmonary complications compared with VAMIE and OE.

129 Pulmonary complications comprised fungal (n = 11), viral

130 Severity of postoperative pulmonary complications computed until hospital discharg

131 Rationale: Pulmonary complications contribute significantly to nonr

132 Pulmonary complications contribute significantly to rheu

133 is study was the occurrence of postoperative pulmonary complications, defined as pneumonia, clinicall

134 Noninfectious pulmonary complications develop frequently in blood and

135 Rates of 30-day postoperative pulmonary complications did not differ between groups (8

136 nic conditions who face frequent cardiac and pulmonary complications during hospitalization more freq

137 Amiodarone has been known to cause pulmonary complications; especially in those with COPD a

138 zing pneumonia (OP) is a known noninfectious pulmonary complication following allogeneic hematopoieti

139 type I IFN-mediated mechanisms can determine pulmonary complications from Pneumocystis infection.

140 y outcome was the incidence of postoperative pulmonary complications from the end of surgery up to po

141 Those with postoperative pulmonary complications had prolonged ICU and hospital l

142 nique over another in reducing postoperative pulmonary complications has not been demonstrated.

143 Cardiac and pulmonary complications have been markedly reduced, wher

144 1.93; 95% CI, 1.28-2.90; P = .002) and major pulmonary complications (HR, 1.85; 95% CI, 1.19-2.86; P

145 2.21; 95% CI, 1.41-3.45; P < .001) and major pulmonary complications (HR, 1.94; 95% CI, 1.21-3.10; P

146 red immunodeficiency syndrome (AIDS)-related pulmonary complications, human immunodeficiency virus-po

147 Acute lung injury (ALI) is a frequent pulmonary complication in critically ill patients.

148 aspergillosis is a Th2 T-lymphocyte-mediated pulmonary complication in patients with atopic asthma an

149 ated protein C (APC) reduced the severity of pulmonary complications in a murine model of chronic gra

150 brane oxygenation have many risk factors for pulmonary complications in addition to their heart failu

151 ent of highly active antiretroviral therapy, pulmonary complications in AIDS are a common clinical pr

152 Late pulmonary complications in bone marrow or stem cell tran

153 To determine the pulmonary complications in HIV-1-infected patients in Da

154 n between tidal volume and the occurrence of pulmonary complications in ICU patients without acute re

155 with an increased incidence of postoperative pulmonary complications in patients who had undergone ge

156 When examining pulmonary complications in patients with FEV1 less than

157 Pulmonary complications in patients with leukemia typica

158 sociated with a lower risk of development of pulmonary complications in patients without acute respir

159 There were no cardiac or pulmonary complications in the lumpectomy group.

160 ion and causes a range of cardiovascular and pulmonary complications in vivo.

161 The most commonly seen pulmonary complications include pleural effusion, hemoth

162 Postoperative pulmonary complications included those defined by the ST

163 Secondary outcomes were postoperative pulmonary complications including development of pulmona

164 tient-related risk factors for postoperative pulmonary complications, including advanced age, America

165 Infection by HIV-1 frequently leads to pulmonary complications, including alterations to local

166 edure-related risk factors for postoperative pulmonary complications, including aortic aneurysm repai

167 urrence and is associated with postoperative pulmonary complications, including aspiration, pneumonia

168 nts are at increased risk for development of pulmonary complications, including chronic obstructive p

169 Postoperative pulmonary complications, including pneumonia, bronchospa

170 Pulmonary complications, including pulmonary fibrosis (P

171 included, 34 (29.6%) developed postoperative pulmonary complications, including two with pneumonia, f

172 Postoperative pulmonary complications increase mortality, length, and

173 ciated with sleep disturbances, tachycardia, pulmonary complications, increased stress response with

174 ed preoperatively, the rate of postoperative pulmonary complications is low and not associated with O

175 The treatment of noninfectious pulmonary complications is not based on randomized clini

176 s patients at highest risk for postoperative pulmonary complications is the need for postoperative me

177 t-onset viral infection causes noninfectious pulmonary complications is unknown.

178 However, the risk of pulmonary complications is very small and outweighed by

179 Late-onset noninfectious pulmonary complications (LONIPC) are a major cause of mo

180 Late-onset noninfectious pulmonary complications (LONIPCs) after allogeneic hemat

181 Pulmonary complications may even be more likely than car

182 ty, wound complications, general infections, pulmonary complications, neurological complications, and

183 herapy was well tolerated with no infectious pulmonary complications noted.

184 Pulmonary complications occur frequently in patients at

185 reased risk of infection, and in particular, pulmonary complications occur frequently.

186 Pulmonary complications occur in the first few days to w

187 Cardiac and pulmonary complications occurred infrequently in the mas

188 TEP was also associated with a lower rate of pulmonary complications (odds ratio = 0.655; 95% confide

189 ciated with the development of postoperative pulmonary complications (odds ratio [OR] for one unit in

190 from the TIME trial showed that MIE reduced pulmonary complications (odds ratio [OR], 0.19; 95% CI,

191 than 38.1% was associated with postoperative pulmonary complications (odds ratio, 4.9; 95% CI, 1.81-1

192 ic pneumonia syndrome (IPS), a noninfectious pulmonary complication of allogeneic bone marrow transpl

193 syndrome (BOS) is a late-onset noninfectious pulmonary complication of allogeneic hematopoietic cell

194 veolar hemorrhage (DAH) is one noninfectious pulmonary complication of BMT.

195 Bronchopulmonary dysplasia is a common pulmonary complication of extreme prematurity.

196 BPD) is a prevalent yet poorly characterized pulmonary complication of premature birth; the current d

197 ial lung disease (RA-ILD) is the most common pulmonary complication of RA, increasing morbidity and m

198 Pulmonary complications of cancer treatment have proven

199 However, non-HCC candidates with pulmonary complications of cirrhosis or cholangiocarcino

200 Non-HCC candidates with pulmonary complications of cirrhosis or cholangiocarcino

201 eption candidates (asHR = 1.27 1.70 2.29 for pulmonary complications of cirrhosis, 1.35 2.04 3.07 for

202 is that NETs may represent drivers of severe pulmonary complications of COVID-19 and suggest that NET

203 ymptomatic HIV-infected individuals from the Pulmonary Complications of HIV Infection Study cohort, p

204 The Pulmonary Complications of HIV Infection Study is a pros

205 y for a potential pathogenic role in chronic pulmonary complications of HIV infection.

206 synthetic glucocorticoids for management of pulmonary complications of HIV infection.

207 To define the pulmonary complications of influenza during the current

208 A review of the literature shows that pulmonary complications of P. vivax are rare but occur m

209 ped iBALT is most prevalent in patients with pulmonary complications of RA and Sjogren syndrome.

210 The pulmonary complications of SCD are of particular importa

211 The pulmonary complications of sickle cell disease include a

212 gans affected in sickle cell disease and the pulmonary complications of sickle cell disease result in

213 cases of female patients presenting typical pulmonary complications of the hyper-Ig E syndrome.

214 Noteworthy among the pulmonary complications of these entities is interstitia

215 l to the community setting, knowledge of the pulmonary complications of transplantation is increasing

216 duce the deleterious impact of postoperative pulmonary complications on clinical outcomes and healthc

217 eomycin chemotherapy was not associated with pulmonary complications or 90-day mortality.

218 obesity did not predispose toward increased pulmonary complications or deep sternal wound infection

219 Induction bleomycin was not associated with pulmonary complications or mortality in patients undergo

220 < 0.001], delirium (OR 3.0, P = 0.004), and pulmonary complications (OR 2.0, P = 0.006).

221 ssure was associated with more postoperative pulmonary complications (OR 3.11, 95% CI 1.39-6.96; p=0.

222 .001), blood transfusion (OR = 2; P = 0.03), pulmonary complications (OR = 4; P < 0.001), unexpected

223 tubation significantly decreased the risk of pulmonary complications (OR, 0.34; 95% CI, 0.15-0.77; P

224 emia (OR, 0.54; 95% CI, 0.31-0.94; P = .03), pulmonary complications (OR, 0.62; 95% CI, 0.41-0.95; P

225 plications (OR, 1.36; 95% CI, 1.19 to 1.57), pulmonary complications (OR, 1.50; 95% CI, 1.29 to 1.74)

226 of protective ventilation on development of pulmonary complications (p=0.027).

227 Postoperative pulmonary complications play an important role in the ri

228 fection, neurologic decompensation (stroke), pulmonary complication (pneumonia, atelectasis, and prol

229 The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory di

230 patitis (n = 36), septic shock (n = 22), and pulmonary complications/pneumonia (n = 13).

231 ain outcome was development of postoperative pulmonary complications (postoperative lung injury, pulm

232 er liver transplantation (LT), postoperative pulmonary complications (PPC) occur in approximately 35%

233 nd reconstruction, which makes postoperative pulmonary complications (PPCs) a noticeable issue among

234 rn, few studies have evaluated postoperative pulmonary complications (PPCs) after non-cardiothoracic

235 Postoperative pulmonary complications (PPCs) after surgery are associa

236 mary outcomes of interest were postoperative pulmonary complications (PPCs) and all-cause complicatio

237 Postoperative pulmonary complications (PPCs) are a leading cause of mo

238 abdominal procedures; however, postoperative pulmonary complications (PPCs) are more frequent in pati

239 preoperative lung function and postoperative pulmonary complications (PPCs) in patients with esophage

240 idney function on the risk of post-operative pulmonary complications (PPCs) is not well known.

241 Postoperative pulmonary complications (PPCs), a leading cause of poor

242 of stay (LOS), total cost, and postoperative pulmonary complications (PPCs).

243 (CCI), Clavien-Dindo complication (CDC), and pulmonary complications (PPCs).

244 ty, general infections, wound complications, pulmonary complications, prolonged stay at the hospital,

245 Pulmonary complications ranging from atelectasis to acut

246 Pulmonary complication rate did not differ between group

247 Pulmonary complication rate was 39% in repairs versus 32

248 ays were associated with lower postoperative pulmonary complication rates compared with hospitals wit

249 Pulmonary complication rates did not differ between grou

250 After adjustment, pulmonary complication rates were lower with COVID-19-fr

251 Pulmonary complications, readmission, and delayed hospit

252 e to a number of complications, particularly pulmonary complications related to scoliosis surgery, em

253 Pulmonary complications result in mortality in adults wi

254 No infections or embolic or pulmonary complications resulted from intra-arterial spl

255 ed frequency of diagnosis-related groups for pulmonary complications, resulting in costs at least as

256 vs 568 mL, P <0.001), a lower percentage of pulmonary complications (RR 0.54; 95% CI, 0.34-0.85; P =

257 omplications (RR = 1.23; 95% CI: 1.09-1.40), pulmonary complications (RR = 1.80; 95% CI: 1.30-2.49),

258 ral infections (RR=1.54, 95% CI: 1.32-1.79), pulmonary complications (RR=1.73, 95% CI: 1.35-2.23), ne

259 1.7 to 2.0) and a median 1.7 (IQR, 1.0-2.0) pulmonary complications score vs 2.1 (95% CI, 2.0-2.3) a

260 The primary endpoint was postoperative pulmonary complications; secondary endpoints were morbid

261 ) to detect ordinal shift in distribution of pulmonary complication severity score (0-to-5 scale, 0,

262 Over the last century, three pulmonary complications specific to chronic liver diseas

263 complications, including anastomotic leaks, pulmonary complications, technical complications, and fu

264 toperative major complications, specifically pulmonary complications, than open esophagectomy, withou

265 ortal hypertension present with three unique pulmonary complications that are the subject of ongoing

266 microflora, which may contribute to chronic pulmonary complications that increasingly are being reco

267 re CAR T-cell therapy and manage cardiac and pulmonary complications that may arise with treatment.

268 The main noninfectious pulmonary complications that present as pulmonary infilt

269 In a multivariable model of pulmonary complications, thoracotomy approach (OR = 1.25

270 patients at increased risk for postoperative pulmonary complications undergoing open abdominal surger

271 es for preventing acute pancreatitis and its pulmonary complication via upregulation of HO-1.

272 The overall rate of pulmonary complications was 21.7% (1832/8439) and 17.8%

273 Occurrence of pulmonary complications was associated with a lower numb

274 hospital death and neurological, renal, and pulmonary complications were evaluated according to etio

275 The rates of preoperative and postoperative pulmonary complications were found to be higher in PI MZ

276 mplications, primarily severe dysphagia, and pulmonary complications were more common after endoscopi

277 Pulmonary complications were only screened for in 19 asy

278 Postoperative pulmonary complications were significantly more common i

279 lation-based study showed that mortality and pulmonary complications were similar for OE and MIE.

280 Pulmonary complications were the most common (n = 1464)

281 Pulmonary complications were the most frequent adverse e

282 urn injury, including a greater incidence of pulmonary complications when compared to younger burn in

283 thoracotomy patients have markedly increased pulmonary complications when compared with VATS patients

284 ruitment strategy could reduce postoperative pulmonary complications, when added to a protective vent

285 ications (including systemic, splanchnic and pulmonary complications), which can eventually culminate

286 f mortality in MFS, patients also experience pulmonary complications, which are poorly understood.

287 Paramount among these are pulmonary complications, which arise as a consequence of

288 AR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the se

289 recruitment strategy resulted in less severe pulmonary complications while in the hospital.

290 ty was both a direct effect and mediated via pulmonary complications, while mechanical, renal replace

291 independently associated with postoperative pulmonary complications, while pulmonary function tests

292 5 adults at increased risk for postoperative pulmonary complications who were scheduled for open abdo

293 eater and substantial risk for postoperative pulmonary complications who were undergoing noncardiac,

294 0.06 (95% CI, -0.11 to -0.01) favoring fewer pulmonary complications with RAMIE.

295 ed immune deficiency syndrome (AIDS)-related pulmonary complications, with a CD4+ T-lymphocyte count

296 tubation, intensive care unit stay and cost, pulmonary complications within 90 days, and 90-day graft

297 The primary outcome was a composite of pulmonary complications within the first 5 postoperative

298 The primary outcome was a composite of pulmonary complications within the first 5 postoperative

299 between groups, did not significantly reduce pulmonary complications within the first 7 postoperative

300 ary outcome was a composite of postoperative pulmonary complications within the first 7 postoperative